Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

  1. Home
  2. Professionals
  3. Michael J. Riella
  1. Back

Michael J. Riella

Partner
Michael Riella
Washington +1 202 662 5168 mriella@cov.com Download V-card
View Less

Michael J. Riella advises clients, principally in the life sciences, health care, gaming, media and technology industries, in a broad range of strategic and financing transactions and in general corporate and securities matters.

Mr. Riella works with clients ranging from development stage companies to large public companies in connection with mergers, acquisitions and divestitures, joint venture arrangements, securities offerings and financing and licensing transactions. He also advises clients on general corporate and securities matters, including federal securities law compliance, corporate governance and executive compensation arrangements.

  • Merck in its:
    • $2.7 billion acquisition of ArQule (NASDAQ: ARQL); and
    • €2.1 billion acquisition of Antelliq Group, a leader in digital animal identification, traceability and monitoring solutions, the fastest growing part of the animal health industry.
  • Aristocrat Leisure Limited in its:
    • $1.28 billion acquisition of Video Gaming Technologies; and
    • $990 million acquisition of Big Fish Games.
  • AstraZeneca in its:
    • $1.26 billion acquisition of Ardea Biosciences
    • $600 million acquisition of Actavis’ branded respiratory business in the U.S. and Canada;
    • $575 million acquisition of Takeda’s respiratory business;
    • acquisition of AlphaCore Pharma by MedImmune, AstraZeneca's biologic arm; and
    • divestitures of multiple pharmaceutical products, including its $325 million divestiture of Myalept® to Aegerion Pharmaceuticals.   
  • Boehringer Ingelheim in:
    • a series of antitrust-driven divestitures of a portfolio of animal health products and a manufacturing facility in connection with Boehringer’s acquisition of Merial (Sanofi’s animal health business); and
    • its $300 million sale of Bedford Laboratories to Hikma Pharmaceuticals.
  • Eisai Inc. in its:
    • strategic manufacturing alliance with Biogen and subsequent sale of its Research Triangle Park manufacturing campus to Biogen;
    • $205 million acquisition of four oncology drugs from Ligand Pharmaceuticals; and
    • divestitures of multiple pharmaceutical products, including its divestiture of U.S. rights to Zonegran® to Concordia Pharmaceuticals, its divestiture of U.S. and Canada rights to Targretin® Gel and Targretin® Capsules to Valeant Pharmaceuticals.
  • Emergent BioSolutions in its:
    • up to $735 million acquisition of Adapt Pharma and its product NARCAN; and
    • in its $270 million acquisition of PaxVax. 
  • Insmed Incorporated in public offerings of over $650 million of common stock and $450 million of convertible senior notes.
  • HealthSouth Corporation in multiple offerings of senior notes.
  • ExxonMobil in structuring and forming the Marine Well Containment Company, a joint venture with Chevron, Shell and ConocoPhillips dedicated to developing and, if needed, deploying, a rapid response system to capture and contain oil in the event of a future deepwater well blowout in the Gulf of Mexico.
  • The Procter & Gamble Company in its 50/50 joint venture with Inverness Medical Innovations, Inc. for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products in a transaction valued at $650 million.
  • Nine television station groups in structuring and forming Pearl Mobile DTV; and Pearl Mobil DTV in structuring and forming Mobile Content Venture LLC, a joint venture among Pearl, Fox Entertainment Group, ION Media Networks and NBC Universal Media LLC.
  • LIN Media in its:
    • issuance of $200 million of senior notes; and
    • acquisition of Red McCombs Media, an online advertising company.   
  • Kamylon Capital in its sale of Forgitron Technologies to Accuride Corporation.
  • JLG Industries in its sale of Gradall Industries.
  • Several NYSE and Nasdaq-listed companies in connection with securities disclosure and corporate governance matters.
  • The D.C. Sports and Entertainment Commission in connection with stadium development and lease arrangements with Major League Baseball and the Washington Nationals.
View More View Less

Pro Bono

  • Advises multiple nonprofit organizations in the DC metropolitan area regarding governance, strategic planning, commercial and general corporate matters.
  • Advises a multinational nonprofit relief organization regarding corporate governance matters.

Memberships and Affiliations

  • American Bar Association
  • The District of Columbia Bar
  • Virginia Bar Association
View Less
  • Legal 500 US, Finance - Capital Markets and M&A/Corporate and Commercial (2017)
  • BTI Client Service All-Star, Corporate (2015)
  • Washington DC Super Lawyers "Rising Star" (2013-2017)

Practices

College of William and Mary, Marshall-Wythe School of Law, J.D., 2002

  • Order of the Coif 
  • William & Mary Law Review

Stetson University, B.A., 1999

  • cum laude 
  • District of Columbia
  • Virginia